Capital rotation in non-core US sectors is accelerating. I'm told that recent Q2 earnings across independent industries show a stark divergence: resource and agricultural sectors are hitting a profitability inflection point, while select biotech and fintech players are being forced into painful strategic retreats.

Nutrien (NTR.US)

Driven by a global agricultural recovery, Nutrien's stock has seen strong momentum, climbing over 17% in the past month. I'm told that the company delivered a net income of USD 1.22B in the second quarter, with diluted EPS of USD 2.53. According to people familiar with the matter, despite distractions from below-market mini-tender offers, management remains optimistic about the volume growth of core fertilizer products in the second half of the year.

IAMGOLD (IAG.US)

Gold producer IAMGOLD has been on a tear recently. The company reported Q2 revenue of USD 856.9M and adjusted EPS of USD 0.42. I'm told that following a massive share price rally over the past three years, the firm was once again recognized as a top performer on the TSX. Its robust USD 1.3B liquidity is currently supporting aggressive share buybacks.

Pan American Silver (PAAS.US)

Silver production jumped 27% year-over-year in the second quarter, driving attributable revenue up 56% to USD 1.27B. Although there are whispers that operational challenges could weigh on 2027 output, insiders point out that the integration of newly acquired assets is effectively hedging these near-term risks.

Bolt Biotherapeutics (BOLT.US)

In the biotech space, Bolt Biotherapeutics is facing a severe reality check. I've learned that the company is slashing its workforce by 50% to conserve cash, as the clinical data release for its lead BDC-4182 program has been pushed back to Q3 2026. With Q2 collaboration revenue plummeting to just USD 5,000 and a net loss of USD 7.7M, whether this restructuring can stretch its runway to 2027 remains an open question.

SurgePays (SURG.US)

This fintech company, which focuses on underserved communities, just offloaded its ClearLine platform for USD 27.5M. Earnings show Q2 revenue grew 40.7% year-over-year to USD 16.2M, successfully restoring GAAP profitability. Industry insiders say eliminating a USD 50M contingent liability was the most significant financial highlight of the quarter.

LexinFintech (LX.US)

Lexin saw its Q2 revenue drop 11.2% year-over-year to RMB 3.187B, while net income plunged 80.2%. I'm told that analysts have drastically slashed their fiscal 2026 earnings estimates. Despite rolling out a USD 50M share repurchase program, concerns over its margin outlook continue to linger.

IDEXX Laboratories (IDXX.US)

Veterinary diagnostics giant IDEXX posted 9% organic revenue growth and 15% earnings growth in Q2. I'm told that at a recent global healthcare conference, management signaled that double-digit growth in recurring revenues could push full-year operating margins above 32%.

Also

• iShares MSCI Australia ETF (EWA.US): With Australia's Q2 inflation cooling down, this ETF tracking core Aussie equities is catching more macro-driven flows.
• iShares iBonds Dec 2025 Term Muni Bond ETF (IBMP.US): This tax-exempt municipal bond ETF continues to serve as a safe-haven allocation amid market volatility.
• TDH Holdings (TDTH.US): The petrochemical distributor has seen muted market action recently, lacking clear catalyst signals.

This article does not constitute investment advice.